News Releases

Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
Almirall enters into a definitive agreement to divest ThermiGen, its medical device aesthetics business
Novel Oral Antibiotic SEYSARA™ (sarecycline) Now Available
Almirall LLC Launches New Name at Fall Clinical Dermatology Congress
Almirall acquires Allergan U.S. medical dermatology portfolio

Media Inquiries
Sam Widdicombe
Senior Director, Strategic Communications
media.us@almirall.com

Almirall PR
almirallpr.us@almirall.com